| Literature DB >> 23892087 |
Bikui Zhang1, Tian Wu, Min Chen, Yulu Zhou, Dongyang Yi, Ren Guo.
Abstract
The role of CD40/CD40 ligand (CD40L) interactions in atherothrombosis, in the response of the immune system to pathogens and in thrombosis is now widely accepted. A role for CD40-CD40L interactions has been identified in atherosclerosis (AS), and such interactions are known to destabilize atherosclerotic plaques by inducing the expression of cytokines, chemokines, growth factors, matrix metalloproteinases and pro-coagulant factors. CD40/CD40L interactions have also been implicated in immune system disorders. Recent studies have suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. Here, we discuss the current drugs that target the CD40/CD40L system, as understanding the roles and regulations of CD40/CD40L-mediated signal pathways by these drugs could facilitate the development of therapeutics that target diverse diseases.Entities:
Keywords: CD40/CD40L; Clopidogrel; Monoclonal antibodies (mAbs); SGN-40; Statins
Mesh：
Substances：
Year: 2013 PMID： 23892087 DOI： 10.1016/j.imlet.2013.07.005
Source DB: PubMed Journal: Immunol Lett ISSN： 0165-2478 Impact factor: 3.685